Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

43.50USD
19 Jun 2019
Change (% chg)

$0.43 (+1.00%)
Prev Close
$43.07
Open
$43.17
Day's High
$43.58
Day's Low
$43.09
Volume
7,667,165
Avg. Vol
6,630,916
52-wk High
$46.46
52-wk Low
$35.88

Select another date:

Tue, Jun 18 2019

Photo

Pfizer makes $10.6 billion cancer bet in cash deal for Array Biopharma

Pfizer Inc said on Monday it would buy Array Biopharma Inc for $10.64 billion in cash, a deal it hopes will help make it a leader in colon cancer and build up its pipeline of oncology drugs.

UPDATE 5-Pfizer makes $10.6 bln cancer bet in cash deal for Array Biopharma

June 17 Pfizer Inc said on Monday it would buy Array Biopharma Inc for $10.64 billion in cash, a deal it hopes will help make it a leader in colon cancer and build up its pipeline of oncology drugs.

Pfizer to buy Array for $10.64 bln

June 17 Pfizer Inc said on Monday it had agreed to acquire Array Biopharma Inc for $10.64 billion, which will grant it access to its cancer drugs.

Novartis hopes Kisqali data will help narrow gap to blockbuster rival

ZURICH Novartis has released data showing sharply improved overall survival rates for its breast cancer drug Kisqali, which the Swiss drugmaker hopes will help it chip away at the dominance of Pfizer's blockbuster Ibrance.

Novartis hopes Kisqali data will help narrow gap to blockbuster rival

ZURICH Novartis has released data showing sharply improved overall survival rates for its breast cancer drug Kisqali, which the Swiss drugmaker hopes will help it chip away at the dominance of Pfizer's blockbuster Ibrance.

Pfizer's atopic dermatitis treatment meets goals in late-stage study

Pfizer Inc's new atopic dermatitis treatment met the main goals in a late-stage study that tested the drug in patients aged 12 and older with moderate to severe forms of the disease, the drugmaker said on Wednesday.

UPDATE 1-Pfizer's atopic dermatitis treatment meets goals in late-stage study

May 15 Pfizer Inc's new atopic dermatitis treatment met the main goals in a late-stage study that tested the drug in patients aged 12 and older with moderate to severe forms of the disease, the drugmaker said on Wednesday.

Pfizer's dermatitis treatment meets main goals of late-stage study

May 15 Pfizer Inc's dermatitis treatment met the main goals in a late-study, testing the drug in patients aged 12 and older with moderate to severe form of the disease, the drugmaker said on Wednesday.

GSK-Pfizer deal gets approval from Australia's anti-trust watchdog

GlaxoSmithKline's deal to buy Pfizer's consumer healthcare business will not lesson competition in Australia, the country's anti-trust regulator said on Thursday as it approved the deal.

Select another date: